-
effectivehealthcare.ahrq.gov/sites/default/files/whitepaper3-lijmer02262010-2.pdf
January 01, 2009 - Premature dissemination of testing technologies can lead
to erroneous diagnoses and preventable delays … The ultimate question in
decisions about testing is how much net gain from testing there will be for … The benefits from testing may be limited to a subset of those tested, so sample size
requirements can … be substantial.45 Trials of testing need a well-defined protocol that links testing,
results, and downstream … All of these practical problems
are challenging but not insurmountable, and trials of testing can be
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/rtc-design-principles_research.pdf
January 01, 2009 - Critical steps in the pathway between testing and patient
outcomes, such as differences in test accuracy … These RCTs should have long-term followup to capture all
immediate and downstream consequences of testing … It may involve no prior testing if the
new test is intended for primary screening or for monitoring … Other pathways
It is possible that the availability of D-dimer lowers the threshold for testing in … Additional patient outcomes and
pathways in evaluations of testing.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/celiac-disease_clinician.pdf
July 01, 2016 - Testing for the presence of HLA-DQ2 or HLA-DQ8 has excellent
sensitivity and negative predictive value … For
children younger than 2 years, the ACG guidelines recommend
initial testing with tTG IgA, DGP IgA … a Sensitivity and specificity values are for point-of-care testing.
b Sensitivity and specificity values … a Sensitivity and specificity values are for point-of-care testing.
b Sensitivity and specificity values … Testing algorithms
�� All algorithms studied used tTG tests.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-252-infantile-epilepsies-disposition-comments.pdf
October 25, 2022 - Since the report did not contain a Key Question
or Contextual Question about genetic testing, it
would … We did look through our database and
identified some studies of genetic testing and
genome sequencing … We did look through our database and
identified some studies of genetic testing and
genome sequencing … We did look through our database and
identified some studies of genetic testing and
genome sequencing … Thank you for this comment, AHRQ may consider
genetic testing for future reports.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/study-design-classification_research.pdf
December 01, 2010 - from the 30 studies used for the first round of
testing. … The
same analyses were conducted for the second round of testing. … Pilot testing the tool in the context
of each review is highly recommended. … The same analyses were conducted for the second round of testing. … We made minor revisions following the final round
of testing that merit further testing.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/procalcitonin_research-protocol.pdf
September 08, 2011 - Direct evidence of the impact of testing on
health outcomes is shown by link A (morbidity, function … , quality of life and/or mortality)
and link G (adverse events of testing). … An early link
in an indirect chain of evidence concerns the diagnostic accuracy of testing (B). … HER2 Testing to Manage Patients With Breast Cancer or Other Solid
Tumors. … The
harms of the testing procedure itself
would relate to venipuncture.
II.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/cancer-quality-indicator-testing_research.pdf
April 01, 2010 - Cancer Quality-ASSIST Supportive Oncology Quality Indicator Set: Feasibility, Reliability, and Validity Testing … Quality-ASSIST supportive oncology quality indicator set: feasibility, reliability, and validity
testing … Cancer Quality-ASSIST supportive oncology quality indicator set: feasibility, reliability, and
validity testing … had both reliability and validity issues, leaving a set of 41 indicators
most promising for further testing … communication are very
different from those assessing discrete, concrete events like fecal occult blood testing
-
effectivehealthcare.ahrq.gov/sites/default/files/infectious-disease-horizon-scan-high-impact-1412.pdf
December 22, 2014 - Standard basic testing for TB costs about $40, and
drug susceptibility testing can add another $102 … As for susceptibility testing, compared with conventional culture-based
susceptibility testing, the … Xpert MTB/RIF point-of-
care testing had similar sensitivity to laboratory-based Xpert MTB/RIF testing … Xpert MTB/RIF into a TB diagnostic algorithm,
TB testing without molecular testing was calculated … When
all health-system costs were considered, TB testing without molecular testing was most costly
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/prostate-cancer-test_disposition-comments.pdf
April 01, 2013 - Disposition of Comments for PCA3 Testing for the Diagnosis and Management of Prostate Cancer
Comparative … Effectiveness Research Review Disposition of Comments Report
Research Review Title: PCA3 Testing … PCA3 Testing for the Diagnosis and Management of Prostate Cancer. … None of the included studies had men enrolled due to
results of PCA3 testing. … TEP # 11 General I read the report "PCA3 testing for ... " with interest.
-
effectivehealthcare.ahrq.gov/sites/default/files/brooks_eccs2012.pdf
January 01, 2012 - Slide 13: Patient Decision Aid
Image of Testing for Prostate Cancer: “Should
I be tested? … men.
• There are
tests
to
find it early.
• We don’t
yet
know
if the benefits of testing … outweigh the risks.
• Men
should learn
about
prostate cancer and testing,
then
decide … if testing
is
the right
choice for them.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-tests-applicability_methods.pdf
July 01, 2012 - In trials is comparator
no testing vs. usual
care with ad hoc
testing. … Bone density testing
reported in relation to
fracture risk reduction
without consideration
of prior … Order of testing
varies across
subjects and was
not randomly
assigned. … The
literature included many studies that did not use gold standards or testing of normals and many … For example, we could not
estimate clinical usefulness of HPV testing among older women from trends
-
effectivehealthcare.ahrq.gov/health-topics/kidney-tests
-
effectivehealthcare.ahrq.gov/sites/default/files/celiac-disease_disposition-comments.pdf
January 28, 2016 - This is the inverse of the KQ4, the
adverse effects of testing. … Would have
liked more discussion about testing in the less
than 3 yr old. … The reader may
be under the impression that this test is on par
with TTG testing. … —that do compare the performance of
testing and the accuracy in standardized serum
samples. … In addition, there are several studies
that have examined variation between labs and in
testing.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/asthma-nitric-oxide_research-protocol.pdf
September 06, 2016 - the diagnosis of asthma is challenging, given their
inability to participate in the usual diagnostic testing … Comparators
KQ 1.a: Standard diagnostic testing of asthma made by healthcare providers based
on history … the available tests (Blood eosinophils, induced sputum,
bronchalveolar lavage, allergy tests (skin testing … • Use of bronchodilators prior to FeNO testing
• Whether appropriate testing protocol was followed … We will iteratively continue
testing the form until no additional items or unresolved questions exist
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0404_01-14-2011.pdf
January 01, 2011 - Intervention(s): Newer drugs (inhaled treprostinil and ambrisentan); combination
therapies; use of testing … antagonists, prostanoids, endothelin
antagonists, phosphodiesterase inhibitors); monotherapy; no use of testing … What are the optimal testing strategies and modalities (vasoreactivity, biomarker)
for guiding the diagnosis
-
effectivehealthcare.ahrq.gov/sites/default/files/infectious-disease-horizon-scan-high-impact-1506.pdf
December 01, 2015 - Standard basic testing for TB costs about $40, and drug
susceptibility testing can add another $102 … As for susceptibility testing, compared with conventional culture-based
susceptibility testing, the … Xpert MTB/RIF point-of-
care testing had similar sensitivity to laboratory-based Xpert MTB/RIF testing … Xpert MTB/RIF into a TB diagnostic algorithm,
TB testing without molecular testing was calculated … When
all health-system costs were considered, TB testing without molecular testing was most costly
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/plasma-cell-dyscrasias-sflc-assay_disposition-comments.pdf
August 23, 2012 - Followup testing was omitted as an intervention
in the definition of KQ5, but the use of FLC, SPEP ( … The frequency of follow up testing
in the various risk groups is certainly an area for more
research … The IMWG criteria
for progression and relapse only use SFLC testing in the
absence of any other signs … Peer Reviewer
#2
General Our clinical practice has incorporated FLC assays into
testing for PCD. … compared to standard
testing alone.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/evidence-summary-cer-197-fractional-exhaled-nitric-oxide.pdf
December 01, 2017 - Fractional exhaled
nitric oxide (FeNO) testing has been
suggested as a diagnostic test for asthma. … years) and children (ages of
5-18 years), using asthma management algorithms
that incorporate FeNO testing … • FeNO testing can identify patients who are more likely
to respond to inhaled corticosteroids (SOE … In children ages 0-4 years with recurrent
wheezing, how accurate is FeNO testing in predicting
the … Key Points
• It is unclear whether FeNO testing in children at ages
0-4 years with symptoms suggestive
-
effectivehealthcare.ahrq.gov/products/colorectal-cancer-screening/research
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0488_12-27-2011.pdf
January 01, 2011 - primarily adults) at high risk for pancreatic cancer (with signs or
symptoms of the disease requiring testing … index.cfm/join-the-email-list1/
Topic Number: 0407
Document Completion Date: 02-14-12
2
invasive testing … (e.g., biopsies and surgery), unnecessary treatment (e.g.,
surgery), unnecessary further testing, and